A-107: Improving Early Detection of Mild Cognitive Impairment Using Cognitive, Sensory, and Blood-Based Markers
Abstract
Objective: Mild cognitive impairment (MCI) is often considered a transitional stage between normal aging and Alzheimer’s disease. Individuals with MCI exhibit cognitive decline that is greater than expected for age but insufficient for a dementia diagnosis. This study evaluated the accuracy of cognitive, olfactory, and blood-based biomarker measures in distinguishing cognitively healthy older adults from those with MCI. Method/Data Selection: Forty-five older adults participated: 21 healthy controls (HC) (M = 73.0 ± 4.49 years) and 24 individuals with MCI (M = 73.5 ± 7.82 years). Controls were recruited from Memory & Aging Lab and the K-State Center on Aging registry; MCI participants were identified from the EPIC database at Stormont Vail Health. Participants completed standardized cognitive assessments, including the Montreal Cognitive Assessment (MoCA), and an odor identification test. In addition, blood was drawn for Alzheimer’s biomarker analysis, including plasma tau-217. Blood samples were processed at Stormont Vail Health Center and analyzed at the University of Kansas Medical Center. Results/Data Synthesis: Results showed that, compared with HC, individuals with MCI had higher plasma tau-217 levels (p = .002), lower MoCA (p = .003), and smell identification test scores (p = .001). Each measure alone classified MCI with moderate accuracy, with area under the curve values of approximately .75, whereas the combined model showed stronger discrimination, with an area under the curve of approximately .90. Supporting image shows classification performance. Conclusions: Findings suggest that cognitive, olfactory, and blood-based biomarkers jointly improve early identification of MCI and may support more accessible screening tools for dementia risk.